Avax Technologies
Avax Technologies, Inc (OTC Pink: AVXT) is a Philadelphia based biotechnology company whose most advanced product candidate is MVax for melanoma. MVax is a cancer vaccine that received a Special Protocol Assessment agreement with the FDA in October 2006, and subsequently began a Phase III registration clinical trial in November 2007 . In previous studies, MVax demonstrated a 5-year overall survival rate (OS)of 44% and response rate of 35% (13% CR, 22% PR).
Wikipage disambiguates
Wikipage redirect
primaryTopic
Avax Technologies
Avax Technologies, Inc (OTC Pink: AVXT) is a Philadelphia based biotechnology company whose most advanced product candidate is MVax for melanoma. MVax is a cancer vaccine that received a Special Protocol Assessment agreement with the FDA in October 2006, and subsequently began a Phase III registration clinical trial in November 2007 . In previous studies, MVax demonstrated a 5-year overall survival rate (OS)of 44% and response rate of 35% (13% CR, 22% PR).
has abstract
Avax Technologies, Inc (OTC Pi ...... rate of 35% (13% CR, 22% PR).
@en
industry
key person
location city
service
type
Link from a Wikipage to an external page
Wikipage page ID
25,516,263
Wikipage revision ID
743,597,239
location country
products
subsid
Genopoietic SA
subject
hypernym
comment
Avax Technologies, Inc (OTC Pi ...... rate of 35% (13% CR, 22% PR).
@en
label
Avax Technologies
@en
wasDerivedFrom
isPrimaryTopicOf
name
Avax Technologies
@en